Annexon to Host Virtual R&D Day on Guillain-Barré Syndrome, Focusing on its Serious Unmet Need and Annexon's Novel Therapeutic Approach [Yahoo! Finance]
Annexon, Inc. - common stock (ANNX)
Company Research
Source: Yahoo! Finance
Willison, MBBS, PhD, Professor Emeritus of Neurology of University of Glasgow, and David Cornblath, MD, Professor Emeritus of Johns Hopkins University School of Medicine BRISBANE, Calif., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for people living with devastating inflammatory-related diseases, today announced it will host a virtual R&D Day on Friday, March 1, 2024 at 10:00 AM ET. To register, click here The event will feature GBS experts who will provide an overview of Guillain-Barré syndrome (GBS), the most common cause of acute neuromuscular paralysis: Lisa Butler , Executive Director, GBS|CIDP Foundation International Hugh Willison, MBBS, PhD , Professor Emeritus of Neurology, University of Glasgow David Cornblath, MD , Professor Emeritus of Neurology, Johns Hopkins University School of Medicine Presentations from GBS experts and Annexon management will
Show less
Read more
Impact Snapshot
Event Time:
ANNX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ANNX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ANNX alerts
High impacting Annexon, Inc. - common stock news events
Weekly update
A roundup of the hottest topics
ANNX
News
- Down -43.02% in 4 Weeks, Here's Why You Should You Buy the Dip in Annexon (ANNX) [Yahoo! Finance]Yahoo! Finance
- Annexon, Inc. (NASDAQ: ANNX) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.MarketBeat
- Are Medical Stocks Lagging Annexon (ANNX) This Year? [Yahoo! Finance]Yahoo! Finance
- Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Annexon, Inc. (NASDAQ: ANNX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $16.00 price target on the stock.MarketBeat
ANNX
Earnings
- 3/26/24 - Beat
ANNX
Sec Filings
- 4/25/24 - Form ARS
- 4/25/24 - Form DEFA14A
- 4/25/24 - Form DEF
- ANNX's page on the SEC website